Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Carcinoma, Non-Small-Cell Lung 242Lung Neoplasms 59Neoplasms 57Head and Neck Neoplasms 57Stomach Neoplasms 56Squamous Cell Carcinoma of Head and Neck 48Parkinson Disease 4, Autosomal Dominant Lewy Body 44Neoplasm Metastasis 40Small Cell Lung Carcinoma 38Urinary Bladder Neoplasms 28Uterine Cervical Neoplasms 26Esophageal Neoplasms 25Colorectal Neoplasms 24Cholangiocarcinoma 24Biliary Tract Neoplasms 24Carcinoma 23Ovarian Neoplasms 21Carcinoma, Transitional Cell 18Carcinoma, Squamous Cell 17Recurrence 16Esophageal Squamous Cell Carcinoma 16Melanoma 13Breast Neoplasms 13Non-Squamous Non-Small Cell Lung Cancer 12Mesothelioma, Malignant 12Mesothelioma 12Nasopharyngeal Carcinoma 11Endometrial Neoplasms 11Adenocarcinoma 11Gallbladder Neoplasms 10

Interventions

regorafenib 1Paclitaxel 1Everolimus 1Etoposide 1Cisplatin 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Unresectable Locally Advanced or Metastatic Solid Tumors × Cisplatin × Clear all
NCT06682611 2024-11-12

Safety and Efficacy of SYHA1813 Single Agent or in Combination With Different Regimens in Unresectable Locally Advanced or Metastatic Solid Tumors.

Shanghai Runshi Pharmaceutical Technology Co., Ltd

Phase 1/2 Not yet recruiting
380 enrolled
Other solid neoplasm

Unresectable Locally Advanced or Metastatic Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡